Author

Fanélie Jouenne

Observed names: F Jouenne, F. Jouenne, Fanelie Jouenne, Jouenne, Fanélie

Institutions: Centre National de la Recherche Scientifique, Inserm, Université Paris Cité, Assistance Publique – Hôpitaux de Paris, Hôpital Saint-Louis, HIPI - Immunologie humaine, physiopathologie et immunithérapie, Optimisation Thérapeutique en Neuropsychopharmacologie, Institut de recherche Saint-Louis

Observed institutions: Centre National de la Recherche Scientifique, National Institutes of Health, Inserm, Université Paris Cité, Université Paris-Saclay, Institut Gustave Roussy, Sorbonne Paris Cité, Assistance Publique – Hôpitaux de Paris, National Cancer Institute, Hôpital Saint-Louis, Immunologie intégrative des tumeurs et immunothérapie du cancer, Université Paris Diderot, HIPI - Immunologie humaine, physiopathologie et immunithérapie, Optimisation Thérapeutique en Neuropsychopharmacologie, Division of Cancer Epidemiology and Genetics, Institut de recherche Saint-Louis, Fondation Gustave Roussy

ORCID: 0000-0002-6706-7424

Observed ORCID: 0000-0002-6706-7424

OpenAlex ID: A5061936655

Rare missense variants in POT1 predispose to familial cutaneous malignant melanoma

2014 · NCI DCEG Cancer Sequencing Working Group, Jianxin Shi, et al. · Nature Genetics · 331

CD147 Is a Promising Target of Tumor Progression and a Prognostic Biomarker

2019 · Alexandra Landras, Coralie Reger de Moura, et al. · Cancers · 139

PDF

Atypical BRAF and NRAS Mutations in Mucosal Melanoma

2019 · Nicolas Dumaz, Fanélie Jouenne, et al. · Cancers · 87

PDF

Macrophage-derived CXCL9 and CXCL11, T-cell skin homing, and disease control in mogamulizumab-treated CTCL patients

2021 · Adèle de Masson, Delphine Darbord, et al. · Blood · 74

PDF

Genetic landscape of adult Langerhans cell histiocytosis with lung involvement

2019 · Fanélie Jouenne, Sylvie Chevret, et al. · European Respiratory Journal · 66

PDF

Melanoma Risk and Melanocyte Biology

2020 · J Bertrand, E Steingrimsson, et al. · Acta Dermato Venereologica · 50

PDF

Discoidin domain receptors: A promising target in melanoma

2019 · Coralie Reger de Moura, Maxime Battistella, et al. · Pigment Cell & Melanoma Research · 38

Response to Trametinib of a Pulmonary Langerhans Cell Histiocytosis Harboring a MAP2K1 Deletion

2018 · Gwenaël Lorillon, Fanelie Jouenne, et al. · American Journal of Respiratory and Critical Care Medicine · 38

Porocarcinomas with PAK1/2/3 fusions: a series of 12 cases

2024 · Thibault Kervarrec, Danna Westphal, et al. · Histopathology · 29

PDF

Recurrent PAK2 rearrangements in poroma with folliculo‐sebaceous differentiation

2023 · Thibault Kervarrec, Daniel Pissaloux, et al. · Histopathology · 29

PDF

Phase I–II Open-Label Multicenter Study of Palbociclib + Vemurafenib in BRAF V600MUT Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism

2021 · Baptiste Louveau, Matthieu Resche-Rigon, et al. · Clinical Cancer Research · 21

Paraneoplastic pemphigus uncovers distinct clinical and biological phenotypes of western unicentric Castleman disease

2023 · Yannick Dieudonné, Marc‐Antoine Silvestrini, et al. · British Journal of Haematology · 20

PDF

Germline CDKN2A/P16INK4A mutations contribute to genetic determinism of sarcoma

2017 · Fanélie Jouenne, Isaure Chauvot de Beauchene, et al. · Journal of Medical Genetics · 20

PDF

Conservative management is effective in unicystic ameloblastoma occurring from the neonatal period: A case report and a literature review

2019 · Anne Morice, Cecilia Neiva, et al. · Oral Surgery Oral Medicine Oral Pathology and Oral Radiology · 19

Primary cutaneous NUT adnexal carcinoma: morphologic, genetic and methylation analysis of seven new cases with comparison to extracutaneous NUT carcinoma and NUTM1‐rearranged porocarcinoma

2025 · Mélanie Legrand, Baptiste Louveau, et al. · Histopathology · 18

Mitogen-activating protein kinase pathway alterations in Langerhans cell histiocytosis

2020 · Fanélie Jouenne, Amira Benattia, et al. · Current Opinion in Oncology · 18

A targeted genomic alteration analysis predicts survival of melanoma patients under BRAF inhibitors

2019 · Baptiste Louveau, Julie Delyon, et al. · Oncotarget · 17

PDF

TERT Expression Induces Resistance to BRAF and MEK Inhibitors in BRAF-Mutated Melanoma In Vitro

2023 · Julie Delyon, Anaïs Vallet, et al. · Cancers · 16

PDF

Intermittent Versus Continuous Dosing of MAPK Inhibitors in the Treatment of BRAF-Mutated Melanoma

2019 · Coralie Reger de Moura, Laetitia Vercellino, et al. · Translational Oncology · 16

RASA1 loss in a BRAF-mutated Langerhans cell sarcoma: a mechanism of resistance to BRAF inhibitor

2019 · F. Jouenne, C. Reger de Moura, et al. · Annals of Oncology · 15

PDF

Pulmonary Langerhans cell histiocytosis – an update on pathogenesis and treatment

2023 · Fanélie Jouenne, Amira Benattia, et al. · Current Opinion in Pulmonary Medicine · 14

Baseline Genomic Features in BRAFV600-Mutated Metastatic Melanoma Patients Treated with BRAF Inhibitor + MEK Inhibitor in Routine Care

2019 · Baptiste Louveau, Fanelie Jouenne, et al. · Cancers · 13

PDF

Discoidin Domain Receptors in Melanoma: Potential Therapeutic Targets to Overcome MAPK Inhibitor Resistance

2020 · Coralie Reger de Moura, Marco Prunotto, et al. · Frontiers in Oncology · 12

PDF

Dramatic Response After Switching MEK Inhibitors in a Patient With Refractory Mixed Histiocytosis

2022 · Anais Roeser, Fanelie Jouenne, et al. · Journal of Hematology · 11

The MAPK Pathway in Pulmonary Langerhans Cell Histiocytosis

2022 · Fanélie Jouenne, Abdellatif Tazi · Archivos de Bronconeumología · 10

Works count: 97

Citation count: 1,255

H-index: 17

I10-index: 29